These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38521630)

  • 1. Comparison of Outcomes in Patients Requiring Mechanical Circulatory Support Who Received Cangrelor in Addition to Anticoagulation Versus Anticoagulation Alone.
    Martin TC; Duewell BE; Juul JJ; Rinka JRG; Rein L; Feih JT
    J Cardiothorac Vasc Anesth; 2024 Jun; 38(6):1328-1336. PubMed ID: 38521630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
    Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R
    Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices.
    Fahnhorst SE; Beasley G; Goldberg JF; Martinez HR; Ryan KA; Towbin JA; Boston U; Absi M
    Artif Organs; 2021 Jan; 45(1):38-45. PubMed ID: 33180355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
    Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
    Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Cangrelor Use After Percutaneous Coronary Intervention in Patients With Mechanical Circulatory Support.
    Pluenneke JC; Mohamed AM; Hayes CH; Berry TP; Thomas EL; Zhurav L; Kozinn JB; Haines MM; Welge JA
    J Cardiothorac Vasc Anesth; 2023 Dec; 37(12):2511-2516. PubMed ID: 37775345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
    JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
    Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
    JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Use of Cangrelor With Heparin During Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Who Require Cardiovascular Surgery: A Case Series.
    Gernhofer YK; Banks DA; Golts E; Pretorius V
    Semin Thorac Cardiovasc Surg; 2020 Winter; 32(4):763-769. PubMed ID: 31610233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of anticoagulants and outcomes in STEMI patients undergoing PPCI in the US hospitals: Bivalirudin, heparin plus GPI or heparin alone?
    Plent S; Mitchell M; Fan W; Werner R
    Hosp Pract (1995); 2015; 43(3):164-71. PubMed ID: 26190670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.
    Erlinge D; Omerovic E; Fröbert O; Linder R; Danielewicz M; Hamid M; Swahn E; Henareh L; Wagner H; Hårdhammar P; Sjögren I; Stewart J; Grimfjärd P; Jensen J; Aasa M; Robertsson L; Lindroos P; Haupt J; Wikström H; Ulvenstam A; Bhiladvala P; Lindvall B; Lundin A; Tödt T; Ioanes D; Råmunddal T; Kellerth T; Zagozdzon L; Götberg M; Andersson J; Angerås O; Östlund O; Lagerqvist B; Held C; Wallentin L; Scherstén F; Eriksson P; Koul S; James S
    N Engl J Med; 2017 Sep; 377(12):1132-1142. PubMed ID: 28844201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic Stewardship: Evaluation of Platelet Reactivity-Guided Cangrelor Dosing Using the VerifyNow Assay.
    Connery A; Ahuja T; Katz A; Arnouk S; Zhu E; Papadopoulos J; Rao S; Merchan C
    J Cardiovasc Pharmacol; 2024 May; 83(5):482-489. PubMed ID: 38335531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalirudin versus heparin, without glycoprotein inhibition, in percutaneous coronary intervention: A comparison of ischemic and hemorrhagic outcomes over 10years.
    Chaudry HI; Curran TB; Andrus BW; Conley SM; DeVries JT
    Cardiovasc Revasc Med; 2018; 19(3 Pt B):338-342. PubMed ID: 29055661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials.
    Verdoia M; Barbieri L; Parodi G; Bellandi B; Schaffer A; Suryapranata H; De Luca G
    Catheter Cardiovasc Interv; 2017 Oct; 90(4):553-565. PubMed ID: 28471057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.
    Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL;
    J Am Coll Cardiol; 2017 Jan; 69(2):176-185. PubMed ID: 28081827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
    Groves EM; Bhatt DL; Steg PG; Deliargyris EN; Stone GW; Gibson CM; Hamm CW; Mahaffey KW; White HD; Angiolillo DJ; Prats J; Harrington RA; Price MJ
    Circ Cardiovasc Interv; 2018 Apr; 11(4):e005635. PubMed ID: 29632238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.
    Jovin IS; Shah RM; Patel DB; Rao SV; Baklanov DV; Moussa I; Kennedy KF; Secemsky EA; Yeh RW; Kontos MC; Vetrovec GW
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1102-1111. PubMed ID: 28527778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
    Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.